Amneal Pharmaceuticals (AMRX) Share-based Compensation (2018 - 2026)

Amneal Pharmaceuticals' Share-based Compensation history runs 9 years deep, the most recent figure standing at $8.8 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 21.47% year-over-year to $8.8 million; the TTM figure through Mar 2026 stood at $33.5 million (up 18.4% YoY), while the FY2025 annual figure was $32.0 million, up 15.07% from the prior year.
• Share-based Compensation was $8.8 million for Q1 2026 at Amneal Pharmaceuticals, up from $8.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $8.8 million in Q1 2026 to a low of $6.0 million in Q4 2023.
• Historically, Share-based Compensation has averaged $7.5 million across 5 years, with a median of $7.6 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation soared 51.31% in 2022, then retreated 23.71% in 2023.
• A 5-year view of Share-based Compensation shows it stood at $7.8 million in 2022, then declined by 23.71% to $6.0 million in 2023, then climbed by 20.69% to $7.2 million in 2024, then increased by 13.76% to $8.2 million in 2025, then advanced by 7.49% to $8.8 million in 2026.
• The last three Share-based Compensation figures came in at $8.8 million (Q1 2026), $8.2 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.